Orphinic selects promising projects in therapeutics, MedTech, and e-Health, verifies research hypotheses through clinical trials, and partners with large pharmaceutical companies.

Orphinic

Orphinic Scientific S.A. was funded in 2019 as the first Polish biotech portfolio platform creating innovative solutions for orphan diseases and other indications with significant unmet medical needs in the clinical trial phase. 
Orphinic core scientific team consist of experts with over 20 years experience in clinical development processes and their commercialization. The company’s competencies in clinical stage development are further enforced through a collaboration with a large clinical CRO operating in the CEE region. This facilitates access to diverse patient populations and rapid enrollment to clinical trials supporting our projects and significantly shortens the duration of individual phases.
Orphinic currently has 8 projects in the pipeline that range from a preclinical phase to market approval stages in three healthcare segments: therapeutics, medtech and e-health.

⏱ We shorten time to the market due to specialized healthcare centers in CEE and an affiliated CRO. 
🩺 Our team has an exceptional track record in sourcing and exiting high-quality projects. 
🧬 Our portfolio represents clinic-ready assets, with first projects ready to exit in 2023, and a preclinical pipeline for long-term value creation.
💊 We invest in projects with low correlation. Average project risk of c.50% with average returns of c.10x our investment.
📈 Our plan is to IPO at Warsaw Stock Exchange by the end of 2022.
 

Orphinic Scientific

👉 "We will eventually cope with cancer 🦀, the challenge is to maintain cognitive functions 🙇. In an ideal world, medical students 👩‍⚕️ will learn primarily how to communicate with patients🤳 , leaving the diagnosis to the power of artificial intelligence that analyzes medical data in a second 🤖,"  believes Adam Kruszewski, MD,  CEO and co-founder of the biotechnology holding Orphinic Scientific. His essay on medicine of the future was published by the mZdrowie.pl.
📕 https://lnkd.in/d95STW34

The BIO International Convention is the largest and most comprehensive event for biotechnology. Let's meet 🤝

#BIO2024 #BioTech #OneonOne #Partnering

📣 As you already know💡, Orphinic Scientific became a finalist of the "Entrepreneur of the Year of the University of Warsaw" competition in the start-up category three weeks ago 🏆.

👉 "We are a company that helps inventors fulfill their dreams and commercialize new drug therapies. In addition, as a firm from Poland, we entered the world's first league," says Adam Kruszewski, CEO of Orphinic.

🎥 Watch our short video: https://lnkd.in/deeyY3T4.

Orphinic Scientific portfolio company DEBN Sp. z o.o. has announced the start of clinical trials of DEBN, the first medical device that enables simultaneous organ-targeted delivery of antibiotics during prostate biopsy procedures.
This innovation comes at a critical time as new research forecasts that global deaths from prostate cancer will almost double in the next 20 years. 

Read more about it here: https://lnkd.in/gdh_H9WA
#ProstateCancer #MedicalDevice #ClinicalTrials #Innovation

Metric
Company Name	Orphinic
Symbol
MSH ID	COM:ORPHINIC
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology and Pharmaceutical
Country	PL
Stage
Employee Count	12
Website	orphinic.com
LinkedIn	orphinic-scientific
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	14
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ORPH

COM:ORPHINIC

Orphinic

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue